You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 11,266,799


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,266,799 protect, and when does it expire?

Patent 11,266,799 protects TRUDHESA and is included in one NDA.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 11,266,799
Title:In-line nasal delivery device
Abstract: A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.
Inventor(s): Fuller; Christopher (Seattle, WA), Hoekman; John D. (Seattle, WA), Kohring; Craig (Seattle, WA)
Assignee: Impel Neuropharma, Inc. (Seattle, WA)
Application Number:15/759,447
Patent Claim Types:
see list of patent claims
Compound; Delivery; Device;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 11,266,799: A Detailed Analysis

Introduction

Patent 11,266,799, like any other patent, is a complex document that outlines the scope and claims of an invention. To fully comprehend its implications, it is crucial to delve into the specifics of its claims, the patent landscape, and the relevant guidelines that govern its eligibility.

The USPTO and Patent Eligibility

The United States Patent and Trademark Office (USPTO) plays a pivotal role in granting patents and ensuring that inventions meet the criteria for patent eligibility. Recent updates, such as the 2024 USPTO guidance on AI patent eligibility, have refined the process for determining the patentability of inventions, especially those involving artificial intelligence[1].

Subject Matter Eligibility

A key aspect of patent eligibility is subject matter eligibility, governed by Section 101 of the U.S. patent laws. The 2024 USPTO guidance emphasizes the importance of integrating judicial exceptions into practical applications. For a claim to be patent-eligible, it must go beyond mere abstract ideas or routine data processing steps and provide a meaningful limit that transforms the exception into a practical application[1].

Claim Structure and Analysis

To analyze the scope and claims of Patent 11,266,799, one must examine the structure of its claims. Here are some critical points:

Independent and Dependent Claims

Independent claims stand alone and define the invention without reference to other claims. Dependent claims, on the other hand, refer back to and further limit an independent claim. The analysis of these claims can provide insights into the breadth and specificity of the invention[5].

Claim Length and Count

Research has shown that the length and count of independent claims can be metrics for measuring patent scope. Narrower claims at publication are often associated with a higher probability of grant and a shorter examination process[5].

Practical Application

For a claim to be patent-eligible, it must demonstrate a practical application that goes beyond abstract ideas. For example, if a claim involves mathematical algorithms, it must specify how these algorithms are used in a real-world setting to provide tangible benefits[1].

Example Analysis from 2024 USPTO Guidance

The 2024 USPTO guidance provides examples that illustrate the distinction between patent-eligible and ineligible claims. For instance, Claim 1 might involve receiving audio input, separating audio signals, and applying mathematical algorithms, which is considered an abstract idea without a practical application. In contrast, Claim 2, which specifies the use of separated audio components in a speech recognition system, is considered patent-eligible because it integrates the abstract idea into a practical application[1].

Inventorship and Patent Ownership

Determining the true and only inventors is crucial for the validity of a patent. U.S. patent law requires that the inventors listed are those who conceived the idea and reduced it to practice. Incorrect or incomplete identification of inventors can lead to challenges and potential invalidation of the patent[4].

Patent Scope and Examination Process

The scope of a patent can change during the examination process. Research indicates that the examination process tends to narrow the scope of patent claims, and this narrowing is more significant when the duration of examination is longer. This process ensures that the granted patent is clear, valid, and does not overly broaden the scope of the invention[5].

Real-World Applications and Benefits

To bolster the argument for patent eligibility, it is essential to highlight the real-world applications and benefits of the claimed method or system. Demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field is crucial. This approach ensures that the invention offers a tangible outcome that directly benefits the technology[1].

Case Law and Recent Developments

The incorporation of recent case law is vital in understanding the evolving landscape of patent eligibility. The 2024 USPTO guidance, for instance, reflects the latest judicial interpretations and provides practitioners with tools to draft claims that are more likely to avoid Section 101 rejections[1].

AI-Assisted Inventions

The role of AI in the development of inventions is clarified in the 2024 USPTO guidance. It emphasizes that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[1].

Data and Statistics

Analyzing patent claims data can provide valuable insights into the patent landscape. The USPTO's Patent Claims Research Dataset, for example, contains detailed information on claims from U.S. patents granted between 1976 and 2014 and U.S. patent applications published between 2001 and 2014. This data can help in understanding trends and metrics related to patent scope and eligibility[3].

Key Takeaways

  • Subject Matter Eligibility: Claims must integrate judicial exceptions into practical applications to be patent-eligible.
  • Claim Structure: Independent and dependent claims must be carefully crafted to define the invention clearly.
  • Practical Application: Claims must demonstrate real-world applications and tangible benefits.
  • Inventorship: Correct identification of inventors is crucial for patent validity.
  • Patent Scope: The examination process can narrow the scope of patent claims to ensure clarity and validity.
  • AI-Assisted Inventions: AI’s role as a tool does not exclude inventions from eligibility if there is significant human contribution.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patent eligibility?

The 2024 USPTO guidance update refines the process for determining the patent eligibility of AI-related inventions, providing more tools for practitioners to evaluate patentability and draft claims that avoid Section 101 rejections.

How does the USPTO determine subject matter eligibility for AI-related inventions?

The USPTO determines subject matter eligibility by assessing whether a claim integrates a judicial exception into a practical application, ensuring that the claimed invention offers a concrete technological improvement.

What is the role of AI in the development of inventions according to the 2024 USPTO guidance?

The method of invention development, including the use of AI, does not impact subject matter eligibility. The focus remains on the claimed invention itself, ensuring AI-assisted inventions are evaluated on equal footing with other technologies.

Why is correct inventorship important in U.S. patent applications?

Correct inventorship is crucial because U.S. patent law requires that the true and only inventors be listed. Incorrect or incomplete identification can lead to challenges and potential invalidation of the patent.

How does the examination process affect the scope of patent claims?

The examination process tends to narrow the scope of patent claims to ensure clarity and validity. This narrowing is more significant when the duration of examination is longer.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent Eligibility - Mintz.
  2. U.S. Patent and Trademark Office (USPTO) - USA.gov.
  3. Patent Claims Research Dataset - USPTO.
  4. Determining Inventorship for US Patent Applications - Oregon State University.
  5. Patent Claims and Patent Scope - SSRN.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 11,266,799

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Impel Pharms TRUDHESA dihydroergotamine mesylate SPRAY, METERED;NASAL 213436-001 Sep 2, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 11,266,799

PCT Information
PCT FiledSeptember 09, 2016PCT Application Number:PCT/US2016/051169
PCT Publication Date:March 16, 2017PCT Publication Number: WO2017/044897

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.